Zumsemetinib
202406065
Phase 2 small_molecule active
Quick answer
Zumsemetinib for Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer is a Phase 2 program (small_molecule) at Aclaris Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Aclaris Therapeutics
- Indication
- Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active